Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The new screenshot shows only minor user-interface adjustments, such as spacing and header alignment, with no changes to core trial information. There are no edits to the study title, conditions, interventions, eligibility criteria, enrollment, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T20:58:24.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    41 days ago
    Change Detected
    Summary
    - Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.
    Difference
    2%
    Check dated 2025-10-06T05:25:16.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.
    Difference
    0.1%
    Check dated 2025-09-29T03:03:56.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Version bumped from v3.0.1 to v3.0.2; the 'Back to Top' link was removed. No substantive changes to core content, pricing, stock availability, or time-slot availability.
    Difference
    0.1%
    Check dated 2025-09-14T19:12:26.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-07T15:27:28.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of detailed location information for various cities across multiple countries, as well as the inclusion of specific medical terms related to renal cell carcinoma and Tivozanib Hydrochloride. Notably, the facility name and location details have been clarified and expanded.
    Difference
    13%
    Check dated 2025-08-31T11:53:58.000Z thumbnail image

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.